IP ecosystem, entrepreneurs, and sustainable technology companies by Shlevin, Harold H.
© 2010, Georgia Institute of Technology
I P  E c o s y s t e m ,  
E n t r e p r e n e u r s ,  
a n d  
S u s t a i n a b le  T e c h n o l o g y  
C o m p a n i e s
Harold H. Shlevin, PhD
Advanced Technology Development Center
Enterprise Innovation Institute
Georgia Institute of Technology
shlevin@gatech.edu
211/1/10 Enterprise Innovation Institute
Harold H. Shlevin
• 25+ years leadership experience in pharma,
medical devices & vaccines companies.
–CEO Solvay Pharmaceuticals
–Founder CIBA Vision Opthalmics, 
–Founder Tikvah Therapeutics
• PhD, University of Rochester Medical 
School, Postdoc. Mayo Clinic
• Assistant Professor – Mayo Medical School
• Multiple advisory boards of for profit and 
not-for-profit organizations
• Strong regional technology leader
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What is Innovation?
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“Innovation U.” Report
•“Virtually every combination of industry relationship or 
economic development activity can be found at Georgia 
Tech, and in a very real sense, the university is an operating 
partner with Georgia state government in the 
implementation and management of a variety of 
technology-focused initiatives.  P er h a ps  m or e th a n  a n y 
oth er  r es ea r ch  u n i ver s i ty i n  N or th  A m er i ca ,  
econ om i c devel opm en t i s  a n  i n tegr a l ,  cr i ti ca l  
com pon en t of  th e m i s s i on  of  th e G eor gi a  I n s ti tu te 
of  T ech n ol ogy , and this has been true from its 
very inception.”
–Souther n Gr owth Policies B oar d, 2002
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Building an Ecosystem
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GT Research Distribution
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Nutrients
• Recruiting research 
talent—worldwide
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Signs of Life
• Emphasis on 
interdisciplinary 
research
• Research centers 
–Over 100 on campus, 
from textiles to 
nanoscience




• GRA Phase Zero awards
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Natural Selection






• GRA Phase I and II 
awards
• GT Edison Fund
• SBIR Assistance
C o m m e r c i a l i z a t i o n  S e r v i c e s
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Intellectual Property Goals
• Reward the faculty for creation of valuable IP
• Support innovation & strengthen 
research programs
• Strengthen global reputation
• Attract top-quality faculty & students
• Add value to intellectual property
• Strengthen industry relationships
• Create successful entrepreneurs
• Strengthen local technology community
• Help human-kind
1111/1/10 Enterprise Innovation Institute
Converging Challenges
• Increasing number of disclosures drives 
overall demand
• “The World is Flat” 
–Increasing GT demand for overseas filings 
• Drives patent cost from ~$15K to ~$100K
–Increasing competition for research partnerships 
from overseas universities
• Increasing ratio of biotech at GT (requires 
overseas protection)
• USPTO proposed limitations on claims, etc.
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IP Business Development
VentureLab
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VentureLab
• Founded September 2001
–Now a model for other universities
–Part of Enterprise Innovation Institute
• Staff has substantial private-sector 
experience
• Faculty-focused process 
–Risk identification and mitigation
–Venture-backable innovations
• Goal: Successful startup companies based 
on Georgia Tech research
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Money
•Assistance with small-
business grants from eleven 
Federal agencies.
•Grants and loans to 
startups based on Georgia 
university research.
•Equity investments in 
startups with a connection 
to Georgia Tech.
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Georgia SBIR Assistance
• Small business R&D funding available from 
eleven Federal agencies
–NASA, DOD, DOE, NIH, EPA, etc.
• Grants, not loans or equity!
• For help with SBIR and STTR process, visit 
<http://www.innovate.gatech.edu/sbir>.
• Up to $850K available
across two phases of
development
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Georgia Research Alliance
• Recruiting Eminent Scholars from all over 
the world to Georgia
• Investing in university capital equipment
–Over $600 million in last 15 years
• Innovation grant program
–Phase 1: up to $50K to university R&D
–Phase 2: up to $100K to university (must be 
matched—equity, SBIR, sale of services, etc.)
–Phase 3: up to $250K loan to company (must be 
repaid upon success or leaving Georgia)
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GRA Matching Funds
Provides up to 4:1 non-dilutive leverage for 
initial outside investment:
E qu i ty,  O th er  
G r a n ts ,  etc.
Phase I $50K grant to 
university




Phase III $250K loan
T ota l $ 10 0 K $ 4 0 0 K
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Incubation
• Advanced Technology 
Development Center 
(ATDC)
• GRA Phase III loans
• Ga. Seed Capital Fund
• Minority Business 
Enterprise Center
• National VC attention
• Centers of Innovation
–Statewide tech areas
E n t r e p r e n e u r  S e r v i c e s





–Interaction with other entrepreneurs
• Connections
–Connections to people and resources
• Centre 
–Facilities designed for startups
• Credibility 
–Instant recognition
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Cycle of Renewal
• Serves as a bridge to 
Georgia Tech services 
and resources
–Expand interaction with 
key local, state, national 
and international 
corporations
–Seminars, workshops & 
technology briefings
–Access to test beds, 
research labs, unique 
equipment & expertise
S t r a t e g i c  P a r t n e r s  O f f i c e











• More nutrients for the 
ecosystem!
K l a u s  A d v a n c e d  C o m p u t i n g  B l d g .
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Building an Ecosystem
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Electrical Equipment 1 11
Mansfield, Mgmt Sci., Feb., 1986
Sources: Innovation.org, Great Moments in Innovation,  
http://www.innovation.org/index.cfm/nonav/Great_Moments_in_Innovation; NIH, National Institute of Allergy and 
Infectious Disease, Tuberculosis (TB), Age of Optimism, 
http://www3.niaid.nih.gov/topics/tuberculosis/Research/researchFeatures/history/historical_optimism.htm.
1980s – 20001950s – 1970s1900s – 1940s
1930s & 1940s
1932 – First antibiotic (sulfa drugs)
1935 – Discovery of cortisone           
1938 – First epilepsy Rx
1948 – First chemotherapy Rxs
1960s & 1970s
1963 – Measles vaccine
1967 – First beta blocker 
1968 – First anti-rejection medicines 
for organ transplants
1972 – Advances in anesthesia
1977 – First non-surgical treatment 
for ulcers
1978 – First biotech product
(synthetic human insulin)
1990s
1993 – First Alzheimer’s Rx
1994 – New breast cancer Rx
- Polio eradicated in the 
Americas
1995 – AIDS Rx advance (HAART)
1995–97 – Four new classes 
of oral diabetes Rxs
1997–98 – Advance in 
Parkinson’s Therapies
1900–1929
1900 – U.S. life expectancy is 45
1908 – Tuberculosis vaccine
1922 – Insulin for diabetes
1924 – Tetanus vaccine
1928 – Discovery of penicillin
1950s
1950 – Discovery of prednisone
1951 – First Rx for depression
1953 – First leukemia Rx
1954 – Polio vaccine
1958 – First diuretic to treat high 
blood pressure
1980s
1981 – First ACE inhibitor to treat 
high blood pressure
1986 – First monoclonal antibody                 
treatment
1987 – New class of depression 
medicines (SSRIs)
– First AIDS Rx
– First statins to lower 
cholesterol
Selected Advances in the 
20th Century
*Note: “Other” includes medical care provided  by private employers for employees at their work site, 
government spending for non-specified medical care by service usually delivered in schools, military field 
stations, and community centers.
Source: CMS, “National Health Expenditures,” at http://www.cms.hhs.gov/NationalHealthExpendData, 



















Health Care Dollar Spending
Source: CMS, Historical National Health Expenditures by Type of Service and Source of  Funds: Calendar Years 







Total Health Care Spending






In 2006, U.S. National Health Expenditures were $2.1 trillion; without prescription 
medicines, the total would have been $1.9 trillion
Total Health Care Expenditures With and Without Prescription Medicines 
1960–2006
Medicines Account for a Small 
Share of Health Spending Growth
Sources: 1Burrill & Company, analysis for PhRMA, 2010 (Includes PhRMA research associates and 
nonmembers) in PhRMA, “Profile 2010, Pharmaceutical Industry;” PhRMA, “PhRMA Annual Membership 
Survey,” 2010; 2Adapted from E. Zerhouni, Presentation at Transforming Health: Fulfilling the Promise of 
Research, 2007; 3NIH Office of the Budget, “Natiional Institutes of Health: Enacted Appropriations for FY 
2008-FY 2010,” 
http://officeofbudget.od.nih.gov/pdfs/FY11/FY%202010%20Enacted%20Appropriations.pdf. 
There is an ecosystem of 




FDA, all of this is an 
ecosystem that is envied 
in the rest of the world.















Government and biopharmaceutical industry research are complementary
“
“















Number of Compounds in Development, by 
Region,*
1997–20091
*Note: Reflects the number of compounds in clinical trials or awaiting approval as of June of each year. 
Compounds in development for multiple regions are counted in each region for which regulatory approval is 
sought, and multiple indications are counted only once.
Sources: 1Adis R&D Insight, Custom data run, February 2009, January 2010; 2G. Verheugen, “Address to the 
Concluding Session of the European Track” (Lyon) 2005.
…in the late 1980s only 41% of 
the top 50 innovative drugs 
were of American origin, in the 
late 1990s…[it had] climbed to 
62%....  
In 1990, the pharmaceutical 
industry spent 50% more on 
research in Europe than in the 
U.S.  In 2001, the situation 
was reversed with 40% more 
spent in the U.S.2
–Gunter Verheugen, Vice-
President of the European 




Medical Research in U.S. 
Outpaces the Rest Of the World
Sources: Drug Discovery and Development: Understanding the R&D Process, www.innovation.org; CBO, 
Research and Development in the Pharmaceutical Industry, 2006.
Developing a new medicine takes an average of 10–15 years; the Congressional 











0.5 – 2 









































Drug Development Takes Longer
Sources: 1J. DiMasi and H. Grabowski, "The Cost of Biopharmaceutical R&D: Is Biotech Different?," 
Managerial and Decision Economics, 2007; J. DiMasi et al., “The Price of Innovation: New Estimates of Drug 
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The Cost of Developing a 
New Drug Has Increased
Source: 1Tufts Center for the Study of Drug Development, “New drugs entering clinical testing in top 10 
firms jumped 52% in 2003-05,” Impact Report, 2006.
Approximately 20% of self-originated new drugs that enter clinical testing will
receive U.S. marketing approval.1
Clinical Approval Success Rates by Therapeutic 
Class1
Probability of Success for 












1 2 3 4 5 6 7 8 9 10
After-Tax Average R&D Costs
Note: Drug development costs represent after-tax out-of-pocket costs in 2000 dollars for drugs introduced from 1990–94.  The same analysis 
found that the total cost of developing a new drug was $1.3 billion in 2006.  Average R&D Costs include the cost of the approved medicines 
as well as those that fail to reach approval.
Lifetime Sales Compared to Average R&D Costs
New Rx Drugs Introduced Between 1990 and 1994, Grouped by Tenths, by 




































Sources: J. A. Vernon, J. H. Golec, and J.A. DiMasi, "Drug development costs when financial risk is measured 
using the Fama-French three-factor model." Health Economics, (2009). ; J. DiMasi and H. Grabowski, “The Cost of 
Biopharmaceutical R&D: Is Biotech Different?,” Managerial and Decision Economics, 2007.
Few Medicines Are a 
Commercial Success
3711/1/10 Enterprise Innovation Institute
Why Make the Investment?
“Without the sense of security which 
property gives,
The land would still be uncultivated”
F. Quesnay, 1773
3811/1/10 Enterprise Innovation Institute
For Further Information
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